Google
INVA 株価分析 — Innoviva Inc (Healthcare >> Biotechnology)
INVA に関するよくある質問
INVAのPER（株価収益率）は？
Innoviva Inc（INVA）は現在PER 3.11倍で取引されています。
INVAのROE（自己資本利益率）は？
Innoviva IncのROEは37.59%です。
INVAの配当利回りは？
Innoviva Incの配当利回りは0.00%です。
INVAの品質スコア（Quality Score）は？
当社のAIはINVAの総合財務品質を100点中100点と評価しています。収益性・成長性・負債・利益の安定性に基づく評価です。
INVAは今が買い時ですか？
当社AIのタイミングスコアは100点中26点で、テクニカル指標とモメンタムから見た現在価格の相対的な魅力度を示します。
INVAはどのセクターに属しますか？
Innoviva IncはHealthcare >> Biotechnologyセクターに分類されます（NASDAQ市場）
INVA AI Analysis Summary
Our AI summary for INVA: Innoviva Inc (NASDAQ), Healthcare >> Biotechnology sector. The stock currently trades at a P/E of 3.11, ROE of 37.59%, a dividend yield of 0.00%. Its financial Quality Score stands at 100/100 — fundamentals stronger than most of the market. The AI Timing Score is 26/100 — most technical signals do not support an entry at this point. All scores are recomputed automatically after each market close from official exchange data. This is systematically generated analysis, not personalized investment advice.
|
USD 20.97
Price
-0.25
(-1.18%)
Day Change
|
|
|---|
INVA, ファンダメンタルスコアはexcellent ( ファンダメンタル = 100) but テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- OUTPERFORM
- Signal Description
- Company financial health is Excellent
- Reason
-
Company financial health is Excellent from almost all quality indicators
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Momentum indicators aligned on the daily timeframe
In details, quality factors are good , financial health is not quite good , and ability to make profit is good , ...
| Deepscope 分析 |
|
75% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 98 |
| Magic Formula Rank by ROA |
78
GOOD
|
| Magic Formula Rank by ROE |
78
GOOD
|
| Magic Formula Rank by ROIC |
120
|
| Price | 20.97 |
| PBV / Sector |
1.17 / 5.20
GREAT
|
| Earning Per Share | 6.75 |
| PE / Sector |
3.11 / 19.97
GREAT
|
| PEG or PE/Growth / Sector |
0.01 / 1.22
GREAT
|
| Average 1M Daily Value |
13.79 M
GREAT
|
| Average 1W Daily Value |
11.53 M
GREAT
|
| Timing Factors |
|
14% |
| Financial Health |
|
50% |
| ポイントになる統計 |
|
72% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-08-01 08:00:01 |
| Symbol | INVA |
| Name | INNOVIVA INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 73.81 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 1,566.22 / 9,903.94 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 1350 Old Bayshore Highway, Burlingame, CA, United States, 94010
Phone: 650 238 9600
Website: https://www.inva.com
Employees: 159
Sector: Healthcare >> Biotechnology
Description: Innoviva, Inc. operates as a biopharmaceutical company in the United States and internationally. Its royalty portfolio includes RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol, and an inhaled corticosteroid, and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, and ABA, VI. The company also markets GIAPREZA for increasing blood pressure in adults with septic or other distributive shock; XACDURO, a co-packaged for intravenous use for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by Acinetobacter; XERAVA for the treatment of complicated intra-abdominal infections in adults; ZEVTERA an advanced-generation cephalosporin antibiotic for the treatment of staphylococcus aureus bacteremia, as well as with right-sided endocarditis, acute bacterial skin and skin structure infections, and community-acquired bacterial pneumonia; NUZOLVENCE for the treatment of uncomplicated urogenital gonorrhea in adults and adolescents. In addition, the company develops bacteriophages with potential use in a range of infectious and other serious diseases. It has a strategic partnership with Sarissa Capital Management LP; and LABA Collaboration Agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Analyst Ratings & Target Price
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
